{
  "id": "cutaneous-b-cell-lymphoma",
  "names": [
    "Primary cutaneous B-cell lymphomas"
  ],
  "aliases": [
    "cutaneous B-cell lymphoma",
    "primary cutaneous B-cell lymphoma",
    "CBCL"
  ],
  "abbr": [
    "PCBCL",
    "CBCL"
  ],
  "patterns": [
    "primary cutaneous B-cell lymphoma",
    "primary cutaneous B-cell lymphomas",
    "cutaneous B-cell lymphoma",
    "PCBCL",
    "CBCL",
    "PCFCL",
    "PCMZL",
    "PCDLBCL-LT",
    "follicle center lymphoma skin",
    "cutaneous marginal zone lymphoma",
    "cutaneous diffuse large B-cell lymphoma"
  ],
  "primary_tag": "heme_onc",
  "tags": [
    "pathology",
    "heme_onc",
    "msk_derm"
  ],
  "definition": "Group of extranodal **B-cell** non-Hodgkin lymphomas originating in and confined to the skin (no systemic involvement at diagnosis). Includes indolent types ‚Äì **follicle center lymphoma** and **marginal zone** lymphoma ‚Äì and an aggressive type (**diffuse large B-cell lymphoma, leg type**).",
  "why_it_matters": "Primary cutaneous lymphomas are mostly T-cell; B-cell variants are less common (‚âà20% of cases). They have distinct behavior and treatment: most CBCLs are slow-growing skin lesions with excellent prognosis, but the leg-type DLBCL is an outlier that behaves aggressively. Correctly identifying the subtype guides therapy (e.g. avoid overtreatment of indolent lesions versus aggressive chemo for leg-type).",
  "how_youll_see_it": [
    "üìå **Primary cutaneous follicle center lymphoma (PCFCL):** Typically presents in middle age (50s) with one or several firm pink or violaceous **nodules/tumors** on the **scalp, forehead, or trunk**. Lesions are smooth, **non-ulcerated**, and patients **lack B symptoms** (no fevers, weight loss).",
    "üìå **Primary cutaneous marginal zone lymphoma (PCMZL):** Second most common subtype; usually presents in younger adults (mean 40s) with **pink-red papules or nodules** (often multiple) on the **arms (upper extremities)** or trunk. These are indolent lesions (sometimes waxing and waning) and may have associated **plasma cells** on biopsy. A history of **Borrelia** infection is sometimes noted (especially in Europe), but systemic symptoms are absent.",
    "üìå **Primary cutaneous DLBCL, leg type:** An uncommon but aggressive form typically seen in **elderly women**. Presents as one or more rapidly enlarging **red or bluish-red tumors** on the **lower legs**, often with **ulceration**. Lesions tend to grow quickly, and patients may develop regional lymphadenopathy; systemic B symptoms are possible if the disease progresses."
  ],
  "problem_solving": [
    "**Biopsy any persistent, unexplained skin lesion** to confirm diagnosis. If pathology shows a B-cell lymphoma in the skin, perform staging (imaging and labs) to ensure it's truly primary cutaneous (no internal involvement).",
    "**Distinguish subtype to guide therapy:** Follicle center vs marginal zone vs leg-type can be identified by histology and immunophenotype. Indolent subtypes (PCFCL, PCMZL) are typically **CD20‚Å∫/BCL6‚Å∫/BCL2‚Åª** or **BCL2‚Å∫/BCL6‚Åª** respectively, with **no MYC/BCL2 translocation**. Leg-type DLBCL shows **large B-cells** that are **BCL2‚Å∫, MUM1‚Å∫** (non-germinal center phenotype).",
    "**Remember Borrelia:** In PCMZL, especially in endemic regions, check for **Borrelia burgdorferi**. Treatment with **doxycycline** has led to regression in some cases, highlighting a possible infectious trigger.",
    "**Tailor treatment:** Don't overtreat indolent CBCL. A few localized lesions can be managed with surgery or local radiation, whereas leg-type disease (or any evidence of systemic spread) demands aggressive systemic chemoimmunotherapy (R-CHOP)."
  ],
  "differentials": [
    {
      "id": "mycosis-fungoides",
      "hint": "Cutaneous T-cell lymphoma (patches/plaques, CD3‚Å∫/CD4‚Å∫ T-cells) rather than B-cell; often scaly lesions."
    },
    {
      "name": "Cutaneous pseudolymphoma",
      "hint": "Benign **reactive lymphoid hyperplasia** in skin (e.g. due to insect bite, tattoo); can mimic lymphoma but is polyclonal and often regresses."
    },
    {
      "name": "Systemic B-cell lymphoma with skin involvement",
      "hint": "Secondary skin lesions from nodal lymphoma (e.g. **systemic follicular lymphoma**); usually have concurrent lymphadenopathy or **B symptoms**, and often **BCL2** overexpression/t(14;18)."
    }
  ],
  "tricks": [
    "üí° **Follicle center lymphoma lacks 14;18:** Unlike nodal follicular lymphoma, primary cutaneous FCL typically **does not have t(14;18)** and is **BCL2-negative**. This helps confirm the skin lesion is a primary skin lymphoma and not systemic FL.",
    "üí° **\"Leg-type = Ladies & Lethal\":** Primary cutaneous DLBCL, leg type occurs mostly in older **women** on the legs and has a **poor prognosis** (5-year survival ~50% or less). Always treat it with systemic **R-CHOP** chemo (plus rituximab) like an aggressive nodal lymphoma.",
    "üí° **Bugs and B-cells:** Some cutaneous marginal zone lymphomas are linked to **Borrelia** infection. In such cases, **antibiotic** therapy (e.g. doxycycline) can result in lymphoma regression ‚Äì a unique scenario where treating an infection treats the cancer."
  ],
  "exam_appearance": [
    "üè• **Older woman with a leg tumor:** An exam vignette might describe a 70-something female with a rapidly enlarging ulcerated nodule on the lower leg. Biopsy reveals sheets of large atypical B-cells that are CD20‚Å∫, BCL2‚Å∫, MUM1‚Å∫. This points to **primary cutaneous DLBCL, leg type**, which requires aggressive therapy (unlike other skin lymphomas).",
    "üè• **Localized skin nodules without systemic signs:** For example, a middle-aged patient with a few indolent pink nodules on the scalp or arm, no lymphadenopathy or B symptoms, and biopsy shows a B-cell infiltrate that is **BCL2-negative**. This is suggestive of an **indolent primary cutaneous B-cell lymphoma** (follicle center or marginal zone type). Management would be local (excision or radiation) rather than systemic chemo."
  ],
  "treatment": [
    "**Localized indolent CBCL (PCFCL, PCMZL):** For solitary or limited lesions, **surgical excision** or **low-dose radiotherapy** can be curative. If lesions are multiple or recurrent, options include **rituximab** (anti-CD20 monoclonal antibody, given intralesionally or intravenously) and topical or intralesional therapies. In Borrelia-associated cases of PCMZL, **antibiotic** treatment (e.g. doxycycline for 3 weeks) may be tried as first-line.",
    "**Aggressive or widespread disease:** **PCDLBCL, leg type** (and any CBCL with extensive spread) is treated like a systemic lymphoma. The regimen of choice is **R-CHOP** chemotherapy (rituximab + CHOP) often combined with involved-field radiation to the lesion. Staging and systemic evaluation are critical; consider CNS prophylaxis if high risk. *Avoid* aggressive chemo in the indolent subtypes, as it confers no benefit in diseases that behave localized."
  ],
  "red_flags": [
    "üö© **Systemic symptoms or nodes:** Primary CBCLs generally do **not** cause **B symptoms** (fever, night sweats, weight loss) or significant lymphadenopathy. If a patient with presumed cutaneous lymphoma develops systemic symptoms or enlarged nodes, suspect **extracutaneous spread** or an underlying systemic lymphoma ‚Äì this warrants prompt re-evaluation and staging scans.",
    "üö© **Ulceration or rapid growth:** Most indolent CBCL lesions are slow-growing and non-ulcerated. A skin lymphoma lesion that is **rapidly enlarging, painful, or ulcerative**, especially on the **lower leg** of an older patient, is a warning sign for the aggressive leg-type DLBCL. Such cases need urgent therapy escalation."
  ],
  "algorithm": [
    "1. **Biopsy skin lesion ‚Üí** any suspicious or persistent skin lesion is biopsied for histopathology. If a B-cell lymphoma is diagnosed, proceed with staging.",
    "2. **Staging workup ‚Üí** perform imaging (CT/PET scans) and labs (CBC, LDH, etc.) ¬± bone marrow biopsy to **rule out systemic lymphoma**. Absence of extracutaneous disease confirms a primary cutaneous lymphoma.",
    "3. **Subtype classification ‚Üí** dermatopathology review with **immunohistochemistry** to categorize the CBCL subtype (follicle center vs marginal zone vs leg-type). Note key markers: e.g. **BCL6‚Å∫/BCL2‚Åª** suggests follicle center; **BCL2‚Å∫/MUM1‚Å∫** suggests leg-type DLBCL.",
    "4. **Treatment plan ‚Üí** For **indolent subtypes** with limited skin involvement, use **skin-directed therapy**: excision or local radiation (often yields long remissions). For **leg-type or multifocal disease**, treat with **systemic chemoimmunotherapy** (R-CHOP regimen) as per aggressive lymphomas. Add antibiotics if Borrelia-positive (PCMZL). Ensure close follow-up for any new lesions."
  ],
  "images": [
    {
      "src": "https://upload.wikimedia.org/wikipedia/commons/4/4b/SkinTumors-PC181157_02.jpg",
      "alt": "Histopathology of a primary cutaneous diffuse large B-cell lymphoma (leg type) showing sheets of large atypical B cells in the dermis.",
      "credit": {
        "text": "image credit",
        "href": "https://commons.wikimedia.org/wiki/File:SkinTumors-PC181157_02.jpg"
      }
    }
  ],
  "cases": [
    {
      "stem": "A 75‚Äëyear‚Äëold woman presents with a rapidly enlarging skin lesion on her right lower leg. Over 2 months, it grew into a 5 cm red nodule with an ulcerated center. She has no fever or night sweats. No other lesions are noted, and no lymph nodes are palpated on exam.",
      "clues": [
        "Elderly female, large ulcerated leg tumor",
        "Biopsy: diffuse dermal infiltrate of large atypical **CD20‚Å∫ B-cells**",
        "IHC: **BCL2‚Å∫, MUM1‚Å∫, CD10‚Åª** tumor cells",
        "Staging scans show no internal lesions"
      ],
      "answer": "Primary cutaneous diffuse large B-cell lymphoma, leg type",
      "teaching": "Cutaneous leg-type DLBCL typically presents in older women as a rapidly growing, often ulcerated leg tumor. The biopsy showing sheets of large B-cells with BCL2 and MUM1 expression is characteristic of this aggressive subtype. Unlike indolent skin lymphomas, it requires systemic chemotherapy (e.g. R-CHOP) due to its high-risk behavior and propensity to spread."
    }
  ],
  "see_also": [
    "non-hodgkin-lymphoma",
    "lymphoma",
    "hodgkin-lymphoma"
  ],
  "prerequisites": [
    "immunology",
    "non-hodgkin-lymphoma",
    "lymph-node"
  ],
  "sources": [
    {
      "title": "StatPearls: Primary Cutaneous Follicle Center Lymphoma (Uy & Sprowl, 2023)",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK567743/"
    },
    {
      "title": "UpToDate: Primary cutaneous follicle center lymphoma (Zhang & Horwitz, 2025)",
      "url": "https://www.uptodate.com/contents/primary-cutaneous-follicle-center-lymphoma"
    },
    {
      "title": "Medscape: Cutaneous B-Cell Lymphoma (Kempf & Zimmermann, updated 2024)",
      "url": "https://emedicine.medscape.com/article/1099540-overview"
    },
    {
      "title": "WHO-EORTC Classification for Primary Cutaneous Lymphomas (Blood, Willemze et al., 2019)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30635287/"
    }
  ],
  "credits": [
    {
      "display": "EnterMedSchool Team",
      "url": "https://entermedschool.com",
      "role": "Author",
      "avatar": "https://entermedschool.b-cdn.net/wp-content/uploads/2023/03/cropped-leo_transparent_blue.png"
    }
  ]
}